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Abstract
STAT transcription factors were discovered 10 years ago as mediators of interferon-induced
gene expression. They now form an important group, comprising seven members, that are
activated by virtually every cytokine and growth factor. Their critical role in development and
normal cell signaling has been largely determined through the analysis of transgenic mice
lacking individual STAT genes. In addition, cell culture work has further delineated their
importance in cellular transformation, apoptosis, differentiation and growth control. This
review discusses the specific phenotypes of STAT-deficient animals with a focus on STAT5
and STAT3, as these two STAT molecules are required for normal breast development and
involution, respectively, and may play an important role in breast carcinogenesis.
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Introduction
Signal transducers and activators of transcription (STAT)
proteins are latent transcription factors that become acti-
vated by phosphorylation on a single tyrosine (near the
carboxy-terminal of the molecule), typically in response to
extracellular ligands [1,2]. Virtually every cytokine and
growth factor (polypeptide ligands) can cause STAT
phosphorylation through either cytokine receptors plus
associated Jak kinases or growth factors [eg epidermal
growth factor (EGF), platelet-derived growth factor
(PDGF), colony-stimulating factor-1] acting through intrin-
sic receptor tyrosine kinases. This clearly implicates STAT
activation in many different biologic events. An active
STAT dimer is formed via the reciprocal interactions
between the Src homology domain-2 of one monomer and
the phosphorylated tyrosine of the other [3]. The dimers
accumulate in the nucleus, recognize specific DNA ele-
ments, and activate transcription. The STAT proteins are
subsequently inactivated by tyrosine dephosphorylation
and return to the cytoplasm [4,5].
The relevance of STAT activation to growth control is made
apparent in experiments performed in cell lines or animals
that lack specific STAT proteins, by the use of antisense
molecules to specific STATs or by the use of dominant-
negative STAT protein encoding constructs. Of the seven
mammalian STATs: STAT2, STAT4, and STAT6 are acti-
vated by a small defined group of cytokines; and deficien-
cies in these STATs, as determined by murine knockout
experiments, have been used to demonstrate theirhttp://breast-cancer-research.com/content/2/2/086
restricted roles in interferon-g signaling and in T cell devel-
opment (Schindler C, personal communication) [6–9]. In
contrast, STAT1, STAT3, STAT5A, and STAT5B are acti-
vated by a large number of different ligands and frequently
simultaneously by the same ligand, which raises the ques-
tion regarding how these STATs participate in particular
biologic responses (Table 1).
STAT1 promotes growth inhibition and
apoptosis
Interferon-g activates STAT1 almost exclusively, and mice
that lack STAT1 have no innate response to either viral or
bacterial pathogens because defense against these
pathogens usually requires response to interferon [10,11].
Interestingly, over time STAT1-deficient mice develop
spontaneous and chemically induced tumors more readily
than wild-type animals, thus defining STAT1 as a ‘tumor
suppressor’ (Schreiber B, personal communication) [12].
The mechanisms responsible for tumor suppression are not
completely understood, but are in part due to the lack of
tumor surveillance. Work done in tissue culture systems on
STAT1-deficient cells [13,14] has demonstrated an impor-
tant role for STAT1 in ligand-mediated growth arrest and
apoptosis. Thus, there is growing evidence that STAT1
activation frequently leads to antiproliferative and proapop-
totic events, and may partly explain why the lack of this mol-
ecule in vivo leads to increased tumor formation.
STAT5 promotes cell proliferation and is
required for mammopoeisis
Two STAT5 genes exist, which are 96% homologous:
Stat5A and Stat5B. Both STAT5 molecules are ubiqui-
tously expressed and can be activated by many cytokines
(see Table 1), including interleukins, growth hormone, pro-
lactin, EGF, and erythropoietin. In addition, a number of
oncogenes such as those that encode Break Point Cluster
Region/Abelson (BCR/ABL) tyrosine kinase and human
T-cell leukemia virus (HTLV)-1, lead to persistent tyrosine
phosphorylation of STAT5 [15,16]. In hematopoietic cells,
STAT5 has been demonstrated to play a critical role in
regulating apoptosis [17–20], and in promoting prolifera-
tion and cell cycle progression [21,22].
Mammary gland development is defined by the formation
of ductal epithelial cells, which requires estrogen and
EGF, and of lobular alveolar epithelium, which proliferates
in response to prolactin and progesterone [23,24].
STAT5A, which can be activated by EGF and prolactin, is
required for mammopoiesis and lactogenesis, as deter-
mined by knockout experiments [17,25].
The phosphorylated or activated form of STAT5 is quite
low in mammary tissue of virgin animals and during early
pregnancy, but rises dramatically after day 14 of preg-
nancy [26]. Upon weaning the breast involutes, which
coincides with a drop in the levels of activated STAT5
[26]. Differentiation of ductal elements occurs in both
wild-type and knockout mice. However, the extent or
amount of epithelial duct development is decreased in
STAT5 knockout animals [17]. Because both prolactin
and EGF is required for ductal and alveolar growth, the
absolute deficiency of STAT5 (despite the almost nonexis-
tent levels of activated STAT5 in the virgin breast) may
reflect the reduced growth or number of epithelial cells.
The mammary tissue of STAT5A-deficient animals has a
significant paucity of STAT5B protein [25]. STAT5B-defi-
cient animals also have defects in mammopoiesis and lac-
togenesis (although not nearly as severe as in the
STAT5A-deficient animals) [17,27].
In addition to STAT5, EGF, estrogen, and progesterone
are factors that are critical to the development and prolif-
eration of mammary tissue. The temporal and physical
interaction between STAT5 and these other critical factors
has not been well described. However, erbB-2, which can
form a heterodimer with other erbB family members, may
be essential for morphogenesis of the mammary ducts
[28], and erbB-2 as a heterodimer with erB-4 can result in
the activation of STAT5 [29]. The progesterone receptor
can synergize with activated STAT5 in the induction of
transcription from the b-casein gene promoter [30]. These
examples suggest that there may be an interplay between
these critical molecules and pathways in mammary devel-
opment.
STAT3 as a regulator of cellular transformation
and apoptosis in breast development
STAT3 deficiency leads to early embryonic lethality [31].
STAT3, like STAT5, is ubiquitously expressed in most
tissues and is activated by a large number of different
ligands, including EGF, PDGF, interleukin-6, ciliary neu-
Table 1
Cytokines, growth factors and oncogenes that activate signal
transducers and activators of transcription (STAT) proteins
STAT1 STAT3 STAT5
IFNa IL-6, IL-11, OSM, CNTF, LIF IL-2, IL-7, IL-9, IL-15
IFNg IL-10 IL-3, IL-5, GM-CSF




ACRII c/v-Src, v-Eyk, v-Abl, v-Fps EGF





IFN, interferon; IL, interleukin, EGF, epidermal growth factor; PDGF,
platelet-derived growth factor.Breast Cancer Research    Vol 2 No 2 Bromberg
rotrophic factor, oncostatin M, leukemia inhibitory factor,
and granulocyte–macrophage colony-stimulating factor
(see Table 1), as well as by a number of oncogenic tyro-
sine kinases. In normal cells and in animals, ligand-depen-
dent activation of the STATs is a transient process, lasting
for several minutes to several hours. In contrast, in many
cancerous cell lines and tumors, where growth factor dys-
regulation is frequently at the heart of cellular transforma-
tion, STAT3 protein is persistently tyrosine phosphorylated
or activated [32,33]. In studies performed in rodent fibro-
blasts, STAT3 activation has been demonstrated to be
both required and sufficient to mediate cellular transforma-
tion. For example, v-src transformation requires activated
STAT3, and a constitutively active form of STAT3
(STAT3-C) is sufficient for mediating transformation
[34–36]. STAT3 activation appears to play an important
role in preventing apoptosis in multiple myeloma-derived
cell lines [37], squamous cell carcinomas [38], neurons
[39,40], and mycosis fungoides tumor cells [41], and
mediates cell cycle progression in a pro-B cell line [42].
The standard approach for circumventing embryonic
lethality of gene knockouts is the creation of conditional
knockouts, whereby only specific tissues lack the gene
(protein) of interest [43]. Given that STAT3 deficiency
results in death of the embryo, a number of STAT3-condi-
tional knockouts have been generated, demonstrating the
importance of STAT3 in preventing interleukin-6-mediated
apoptosis of T cells [44], and keratinocytes that lack
STAT3 do not migrate properly [45]. These findings, both
in vitro and in vivo, suggest that STAT3 activation can
prevent apoptosis and promotes proliferative processes,
including cellular transformation.
The normal activation pattern of STAT3 in breast develop-
ment and mammopoiesis reveals prominent levels of acti-
vated STAT3 in the virgin breast (presumably in response
to EGF), which decrease somewhat during pregnancy and
lactation, and subsequently increase during involution [26].
The marked increase in phosphorylated STAT3 during
involution coincides with the initial burst of apoptosis.
A recent paper by Chapman et al [46] revealed a require-
ment for activated STAT3 in the involuting (apoptosing)
breast. By crossing a b-lactoglobulin (BLG)–Cre mouse
with a STAT3-null/STAT3-flox mouse, mice were generated
that had a decrease in the levels of STAT3 in the lactating
and involuting breast. The phenotype of the STAT3-defi-
cient mammary gland revealed a delay in involution and
apoptosis, suggesting a proapoptotic role for STAT3 in the
involuting breast. At the molecular level a concomitant
increase in the levels of STAT5 and STAT1 and an
increase in the ‘proapoptotic’ proteins p21, p53 and Bax is
observed in the BLG-Cre/Stat3flox/– breast tissue relative to
the BLG-Cre/Stat3flox/+ tissue. Given the wealth of evi-
dence demonstrating a proliferative and antiapoptotic role
for STAT3 in some cell types, the findings of Chapman et
al are somewhat surprising. Nevertheless, there are a few
notable examples in which STAT3 activation is clearly
responsible for a growth arrest in cultured cells. The first is
in a myeloid tumor-derived cell line, M1, in which inter-
leukin-6-mediated STAT3 activation is clearly responsible
for inducing G1 arrest of these cells [47,48]. The second is
in a macrophage-derived cell line, J774, in which inter-
leukin-10, which activates STAT3, leads to antiproliferation,
and expression of an inducibly active STAT3-gyraseB
chimera mimics the effects of interleukin-10 [49].
The precise mechanism(s) by which STAT3 activation in
the involuting breast leads to apoptosis are not known.
Why activated STAT3 has this paradoxical effect as a
function of cell type is presumably related to differences in
the regulation of STAT3 target genes. For example, acti-
vated STAT3 can upregulate expression of the c-myc
proto-oncogene [35,50]. It is well known that c-myc dys-
regulation can lead to both cellular transformation and
apoptosis, depending on the cell type and the growth con-
ditions [51]. Regardless of the mechanism, it is clear that
STAT3 and STAT5 activation play critical roles in breast
tissue development, probably through their ability to influ-
ence growth, differentiation, and apoptosis.
The relationship between the molecules responsible for
organogenesis and cancer is not known. However, we
believe that, in general, normal proteins and signaling
pathways become abnormally regulated, which leads to
the production of cancer. For example, in the case of
breast cancer dysregulation of erbB-2, transforming
growth factor-a, and estrogen is associated with the for-
mation of breast cancer in human cells and murine
models. STAT3 and STAT5 are clearly involved in breast
organogenesis, and there is increasing evidence that the
STAT proteins (in particular STAT3, STAT5 and STAT1)
are persistently activated in primary breast cancers and
breast cancer-derived cell lines (Bromberg J, et al, and
Jove R, et al, unpublished observations) [32,52]. It is the
persistent nature of STAT activation that is abnormal and
is perhaps sufficient to mediate transformation. The poten-
tial mechanism(s) responsible for STAT tyrosine phospho-
rylation in primary breast cancer specimens are many and
include the overproduction of the EGF receptor and EGF
[38], PDGF receptor, Jak kinases, and c-src [32,53]
(Reddy EP, personal communication), and perhaps muta-
tions within the STAT protein itself. In addition, defects in
the negative regulators of STAT phosphorylation may also
be responsible for the persistence of tyrosine phosphory-
lated STAT3 in these specimens. These negative regula-
tors include tyrosine phosphatases (ie SHP-2); the
suppressor of cytokine signaling (SOC) proteins, which
are negative regulators of the Jak kinases [54]; and the
protein inhibitor of activated STATs (PIAS) [55], which
inhibit activated STATs from binding DNA.Interestingly, a number of STAT3 and STAT5 target genes
(cyclinD1, c-myc [35,50,56] and Bcl-xL [18,35]) are impli-
cated either in breast cancer progression or in prognosis.
Overexpression of cyclinD1 in transgenic models leads to
hyperproliferation of breast tissue, as well as overt carci-
noma [57]. CyclinD1 is overexpressed in preinvasive
breast cancer, such as ductal carcinoma in situ, and in
invasive breast carcinomas [58]. It has also been sug-
gested that overexpression of cyclin D1 protein is impor-
tant in the detection of early stages of breast oncogenesis,
and may play a crucial role in the development of breast
cancer malignancy [58–61]. C-myc, another Stat3 target
gene, when overexpressed correlates with highly prolifera-
tive breast tumors [62–64]. Bcl-xL, a member of the anti-
apoptotic bcl-2 family of proteins, may be associated with
a prognostically favorable phenotype in breast cancer
[65–67]. Now, with the development of mice that lack the
specific STAT proteins, we can begin to dissect the spe-
cific roles of the STATs in breast cancer pathogenesis.
References
1. Darnell JE Jr: STATs and gene regulation. Science 1997, 277:1630–
1635.
2. Stark GR, Kerrr IM, Williams BR, et al: How cells respond to interfer-
ons. Annu Rev Biochem 1998, 67:227–264.
3. Chen X, Vinkemeier U, Zhao Y, et al: Crystal structure of a tyrosine
phosphorylated STAT-1 dimer bound to DNA. Cell 1998, 93:827–
839.
4. Haspel RL, Salditt-Georgieff M, Darnell JE Jr: The rapid inactivation
of nuclear tyrosine phosphorylated Stat1 depends on a protein
tyrosine phosphatase. EMBO J 1996, 15:6262–6268.
5. Haspel RL, Darnell JE Jr: A nuclear protein tyrosine phosphatase is
required for the inactivation of Stat1. Proc Natl Acad Sci USA
1999,  96:10188–10193.
6. Kaplan MH, Schindler U, Smiley ST, et al: Stat6 is required for medi-
ating responses to IL-4 and for development of Th2 cells. Immunity
1996, 4:313–319.
7. Thierfelder WE, van Deursen JM, Yamamoto K, et al: Requirement for
Stat4 in interleukin-12-mediated responses of natural killer and T
cells. Nature 1996, 382:171–174.
8. Takeda K, Tanaka T, Shi W, et al: Essential role of Stat6 in IL-4 sig-
nalling. Nature 1996, 380:627–630.
9. Shimoda K, Deursen JV, Sangster MY, et al: Lack of IL-4-induced
Th2 response and IgE class switching in mice with disrupted
Stat6 gene. Nature 1996, 380:630–633.
10. Meraz MA, White JM, Sheehan KCF, et al: Targeted disruption of the
Stat1 gene in mice reveals unexpected physiologic specificity in
the JAK-STAT signaling pathway. Cell 1996, 84:431–442.
11. Durbin JE, Hackenmiller R, Simon MC, et al: Targeted disruption of
the mouse Stat1 gene results in compromised innate immunity to
viral disease. Cell 1996, 84:443–450.
12. Kaplan DH, Shankaran V, Dighe AS, et al: Demonstration of an inter-
feron gamma-dependent tumor surveillance system in immuno-
competent mice. Proc Natl Acad Sci USA 1998, 95:7556–7561.
13. Bromberg JF, Horvath CM, Wen Z, et al: Transcriptionally active
Stat1 is required for the antiproliferative effects of both IFN-a a and
IFN-g g. Proc Natl Acad Sci USA 1996, 93:7673–7678.
14. Kumar A, Commane M, Flickinger TW, et al: Defective TNF-alpha-
induced apoptosis in STAT1-null cells due to low constitutive
levels of caspases. Science 1997, 278:1630–1632.
15. Shuai K, Halpern J, ten Hoeve J, et al: Constitutive activation of
STAT5 by the BCR-ABL oncogene in chronic myelogenous
leukemia. Oncogene 1996,  13:247–254.
16. Migone TS, Lin JX, Cereseto A, et al: Constitutively activated Jak-
STAT pathway in T cells transformed with HTLV-I. Science 1995,
269:79–81.
17. Teglund S, McKay C, Schuetz E, et al: Stat5a and Stat5b proteins
have essential and nonessential, or redundant, roles in cytokine
responses. Cell 1998, 93:841–850.
18. Socolovsky M, Fallon AE, Wang S, et al: Fetal anemia and apoptosis
of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for
Stat5 in Bcl-X(L) induction. Cell 1999, 98:181–191.
19. Onishi M, Nosaka T, Misawa K, et al: Identification and characteriza-
tion of a constitutively active STAT5 mutant that promotes cell
proliferation. Mol Cell Biol 1998, 18:3871–3879.
20. Nosaka T, Kawashima T, Misawa K, et al: STAT5 as a molecular reg-
ulator of proliferation, differentiation and apoptosis in hematopoi-
etic cells. EMBO J 1999, 18:4754–4765.
21. Moriggl R, Topham DJ, Teglund S, et al: Stat5 is required for IL-2-
induced cell cycle progression of peripheral T cells. Immunity
1999,  10:249–259.
22. Nieborowska-Skorska M, Wasik M, Slupianek A, et al: Signal trans-
ducer and activator of transcription (STAT)5 activation by
BCR/ABL is dependent on intact Src homology (SH)3 and SH2
domains of BCR/ABL is required for leukemogenesis. J Exp Med
1999, 189:1229–1242.
23. Topper YJ, Freeman CS: Multiple hormone interactions in the
developmental biology of the mammary gland. Physiol Rev 1980,
60:1049–1056.
24. Vonderhaar BK: Local effects of EGF, alpha-TGF, and EGF-like
growth factors on lobuloalveolar development of the mouse
mammary gland in vivo. J Cell Physiol 1987, 132:581–584.
25. Liu X, Robinson GW, Wagner K-U, et al. Stat5a is mandatory for
adult mammary gland development and lactogenesis. Genes Dev
1997, 11:179–186.
26. Liu X, Robinson GW, Hennighausen L: Activation of Stat5a and
Stat5b by tyrosine phosphorylation is tightly linked to mammary
gland differentiation. Mol Endocrinol 1996, 10:1496–1506.
27. Udy GB, Towers RP, Snell RG, et al: Requirement of Stat5b for
sexual dimorphism of body growth rates and liver gene expres-
sion. Proc Natl Acad Sci USA 1997, 94:7239–7244.
28. Sebastian J, Richards RG, Walker MP, et al: Activation and function of
the epidermal growth factor receptor and erbB-2 during mammary
gland morphogenesis. Cell Growth Differ 1998, 9:777–785.
29. Olayioye MA, Beuvink I, Horsch K, et al: ErbB receptor-induced acti-
vation of stat transcription factors is mediated by src tyrosine
kinases. J Biol Chem 1999, 274:17209–17218.
30. Stoecklin E, Wissler M, Schaetzle D, et al: Interactions in the tran-
scriptional regulation exerted by Stat5 and by members of the
steroid hormone receptor family. J Steroid Biochem Mol Biol 1999,
69:195–204.
31. Takeda K, Noguchi K, Shi W, et al: Targeted disruption of the
mouse Stat3 gene leads to early embryonic lethality. Proc Natl
Acad Sci USA 1997, 94:3801–3804.
32. Garcia R, Jove R: Activation of STAT transcription factors in onco-
genic tyrosine kinase signaling. J Biomed Sci 1998, 5:79–85.
33. Weber-Nordt RM, Egen C, Wehinger J, et al: Constitutive activation
of STAT proteins in primary lymphoid and myeloid leukemia cells
and in Epstein-Barr virus (EBV)-related lymphoma cell lines.
Blood 1996,  88:809–816.
34. Bromberg JF, Horvath CM, Besser D, et al: Stat3 activation is required
for cellular transformation by v-src. Mol Cell Biol 1998, 5:2553–2558.
35. Bromberg J, Wrzeszczynska M, Devgan G, et al: Stat3 as an Onco-
gene. Cell 1999, 98:295–303.
36. Turkson J, Bowman T, Garcia R, et al: Stat3 activation by Src
induces specific gene regulation and is required for cell transfor-
mation. Mol Cell Biol 1998, 18:2545–2552.
37. Catlett-Falcone R, Landowski TH, Oshiro MM, et al: Constitutive acti-
vation of Stat3 signaling confers resistance to apoptosis in human
U266 myeloma cells. Immunity 1999, 10:105–115.
38. Grandis JR, Drenning SD, Chakraborty A, et al: Requirement of Stat3
but not Stat1 activation for epidermal growth factor receptor-
mediated cell growth in vitro. J Clin Invest 1998, 102:1385–1392.
39. Bonni A, Sun Y, Nadal-Vicens M, et al: Regulation of gliogenesis in
the central nervous system by the JAK-STAT signaling pathway.
Science 1997, 278:477–483.
40. Ihara S, Nakajima K, Fukada T, et al: Dual control of neurite out-
growth by STAT3 and MAP kinase in PC12 cells stimulated with
interleukin-6. EMBO J 1997, 16:5345–5352.
41. Nielsen M, Kaestel CG, Eriksen KW, et al: Inhibition of constitutively
activated Stat3 correlates with altered Bcl-2/Bax expression and
induction of apoptosis in mycosis fungoides tumor cells. Leukemia
1999, 13:735–738.
42. Fukada T, Ohtani T, Yoshida Y, et al. STAT3 orchestrates contradic-
tory signals in cytokine-induced G1 to S cell-cycle transition.
EMBO J 1998, 17:6670–6677.
http://breast-cancer-research.com/content/2/2/086Breast Cancer Research    Vol 2 No 2 Bromberg
43. Kuhn R, Schwenk F, Aguet M, et al: Inducible gene targeting in
mice. Science 1995,  269:1427–1429.
44. Takeda K, Kaisho T, Yoshida N, et al: Stat3 activation is responsible
for IL-6-dependent T cell proliferation through preventing apopto-
sis: generation and characterization of T cell- specific Stat3-defi-
cient mice. J Immunol 1998, 161:4652–4660.
45. Sano S, Itami S, Takeda K, et al: Keratinocyte-specific ablation of
stat3 exhibits impaired skin remodeling, but does not affect skin
morphogenesis. EMBO J 1999, 18:4657–4668.
46. Chapman RS, Lourenco PC, Tonner E, et al: Suppression of epithe-
lial apoptosis and delayed mammary gland involution in mice with
a conditional knockout of STAT3. Genes Dev 1999, 13:2604–2616.
47. Minami M, Inoue M, Wei S, et al: STAT3 activation is a critical step
in gp130-mediated terminal differentiation and growth arrest of a
myeloid cell line. Proc Natl Acad Sci USA 1996, 93:3963–3966.
48. Nakajima K, Yamanaka Y, Nakae K, et al: A centrol role of Stat3 in
IL6 induced regulation of growth and differentiation in M1
leukemia cells. EMBO J 1996. 15:3651–3658.
49. O’Farrell AM, Liu Y, Moore KW, et al: IL-10 inhibits macrophage
activation and proliferation by distinct signaling mechanisms: evi-
dence for Stat3-dependent and -independent pathways. EMBO J
1998, 17:1006–1018.
50. Kiuchi N, Nakajima K, Ichiba M, et al: STAT3 is required for the
gp130-mediated full activation of the c-myc gene. J Exp Med 1999,
189:63–73.
51. Cole MD, McMahon SB: The Myc oncoprotein: a critical evaluation
of transactivation and target gene regulation. Oncogene 1999, 18:
2916–2924.
52. Watson CJ, Miller WR: Elevated levels of members of the STAT
family of transcription factors in breast carcinoma nuclear
extracts. Br J Cancer 1995, 71:840–844.
53. Garcia R, Yu CL, Hudnall A, et al: Constitutive activation of Stat3 in
fibroblasts transformed by diverse oncoproteins and in breast
carcinoma cells. Cell Growth Differ 1997, 8:1267–1276.
54. Naka T, Narazaki M, Hirata M, et al: Structure and function of a new
STAT-induced STAT inhibitor. Nature 1997, 387:924–929.
55. Chung CD, Liao J, Liu B, et al: Specific inhibition of Stat3 signal
transduction by PIAS3. Science 1997, 278:1803–1805.
56. Matsumura I, Kitamura T, Wakao H, et al: Transcriptional regulation
of the cyclin D1 promoter by STAT5: its involvement in cytokine-
dependent growth of hematopoietic cells. EMBO J 1999, 18:
1367–1377.
57. Wang TC, Cardiff RD, Zukerberg L, et al: Mammary hyperplasia and
carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994, 369:
669–671.
58. Weinstat-Saslow D, Merino MJ, Manrow RE, et al: Overexpression of
cyclin D mRNA distinguishes invasive and in situ breast carcino-
mas from non-malignant lesions. Nature Med 1995, 1:1257–1260.
59. Norton L, Rosen PP, Rosen N: Refining the origins of breast cancer.
Nature Med 1995, 1:1250–1251.
60. Gillett CE, Lee AH, Millis RR, et al: Cyclin D1 and associated pro-
teins in mammary ductal carcinoma in situ and atypical ductal
hyperplasia. J Pathol 1998, 184:396–400.
61. Alle KM, Henshall SM, Field AS, et al: Cyclin D1 protein is overex-
pressed in hyperplasia and intraductal carcinoma of the breast.
Clin Cancer Res 1998, 4:847–854.
62. Berns EM, Klijn JG, van Putten WL, et al: c-myc amplification is a
better prognostic factor than HER2/neu amplification in primary
breast cancer. Cancer Res 1992, 52:1107–1113.
63. Nass SJ, Dickson RB: Epidermal growth factor-dependent cell
cycle progression is altered in mammary epithelial cells that over-
express c-myc. Clin Cancer Res 1998, 4:1813–1822.
64. Guerin M, Barrois M, Terrier MJ, et al: Overexpression of either c-myc
or c-erbB-2/neu proto-oncogenes in human breast carcinomas:
correlation with poor prognosis. Oncogene Res 1988, 3:21–31.
65. Nakopoulou L, Michalopoulou A, Giannopoulou I, et al: bcl-2 protein
expression is associated with a prognostically favourable pheno-
type in breast cancer irrespective of p53 immunostaining.
Histopathology 1999,  34:310–319.
66. Liu JR, Fletcher B, Page C, et al. Bcl-xL is expressed in ovarian carci-
noma and modulates chemotherapy-induced apoptosis. Gynecol
Oncol 1998,  70:398–403.
67. Vakkala M, Lahteenmaki K, Raunio H, et al: Apoptosis during breast
carcinoma progression. Clin Cancer Res 1999, 5:319–324.
Author’s affiliation: Laboratory of Molecular Cell Biology, Rockefeller
University, and the Department of Medicine, Memorial Sloan Kettering
Cancer Center, New York, New York, USA
Sponsorship: This review was supported by a grant from the James S.
McDonnell Foundation
Correspondence: Jacqueline Bromberg, Rockefeller University,
1230 York Avenue, New York, NY 10021, USA. Tel: +1 212 327 7448;
fax: +1 212 327 8801; e-mail: brombej@rockvax.rockefeller.edu